PMID- 31594539
OWN - NLM
STAT- MEDLINE
DCOM- 20200505
LR  - 20231014
IS  - 1742-6405 (Electronic)
IS  - 1742-6405 (Linking)
VI  - 16
IP  - 1
DP  - 2019 Oct 8
TI  - Predictors of loss to follow-up in art experienced patients in Nigeria: a 13 year 
      review (2004-2017).
PG  - 30
LID - 10.1186/s12981-019-0241-3 [doi]
LID - 30
AB  - BACKGROUND: Expanded access to antiretroviral therapy (ART) leads to improved 
      HIV/AIDS treatment outcomes in Nigeria, however, increasing rates of loss to 
      follow-up among those on ART is threatening optimal standard achievement. 
      Therefore, this retrospective cross-sectional study is aimed at identifying 
      correlates and predictors of loss to follow-up in patients commencing ART in a 
      large HIV program in Nigeria. METHODS: Records of all patients from 432 US CDC 
      Presidents Emergency Plan for AIDS Relief (PEPFAR) supported facilities across 10 
      States and FCT who started ART from 2004 to 2017 were used for this study. 
      Bivariate and multivariate analysis of the demographic and clinical parameters of 
      all patients was conducted using STATA version 14 to determine correlates and 
      predictors of loss to follow-up. RESULTS: Within the review period, 245,257 
      patients were ever enrolled on anti-retroviral therapy. 150,191 (61.2%) remained 
      on treatment, 10,960 (4.5%) were transferred out to other facilities, 6926 (2.8%) 
      died, 2139 (0.9%) self-terminated treatment and 75,041 (30.6%) had a loss to 
      follow-up event captured. Males (OR: 1.16), Non-pregnant female (OR: 4.55), 
      Patients on >/= 3-monthly ARV refills (OR: 1.32), Patients with un-suppressed viral 
      loads on ART (OR: 4.52), patients on adult 2nd line regimen (OR: 1.23) or 
      pediatric on 1st line regimen (OR: 1.70) were significantly more likely to be 
      lost to follow-up. CONCLUSION: Despite increasing access to anti-retroviral 
      therapy, loss to follow-up is still a challenge in the HIV program in Nigeria. 
      Differentiated care approaches that will focus on males, non-pregnant females and 
      paediatrics is encouraged. Reducing months of Anti-retroviral drug refill to less 
      than 3 months is advocated for increased patient adherence.
FAU - Aliyu, Ahmad
AU  - Aliyu A
AD  - Institute of Human Virology Nigeria (IHVN), Abuja, Nigeria.
FAU - Adelekan, Babatunde
AU  - Adelekan B
AD  - Institute of Human Virology Nigeria (IHVN), Abuja, Nigeria. 
      babalekan2000@yahoo.com.
AD  - Academy for Health Development, Ife, Nigeria. babalekan2000@yahoo.com.
FAU - Andrew, Nifarta
AU  - Andrew N
AD  - Institute of Human Virology Nigeria (IHVN), Abuja, Nigeria.
FAU - Ekong, Eunice
AU  - Ekong E
AD  - Institute of Human Virology Nigeria (IHVN), Abuja, Nigeria.
FAU - Dapiap, Stephen
AU  - Dapiap S
AD  - Institute of Human Virology Nigeria (IHVN), Abuja, Nigeria.
FAU - Murtala-Ibrahim, Fati
AU  - Murtala-Ibrahim F
AD  - Institute of Human Virology Nigeria (IHVN), Abuja, Nigeria.
FAU - Nta, Iboro
AU  - Nta I
AD  - Institute of Human Virology Nigeria (IHVN), Abuja, Nigeria.
FAU - Ndembi, Nicaise
AU  - Ndembi N
AD  - Institute of Human Virology Nigeria (IHVN), Abuja, Nigeria.
FAU - Mensah, Charles
AU  - Mensah C
AD  - Institute of Human Virology Nigeria (IHVN), Abuja, Nigeria.
FAU - Dakum, Patrick
AU  - Dakum P
AD  - Institute of Human Virology Nigeria (IHVN), Abuja, Nigeria.
LA  - eng
GR  - PEPFAR/PEPFAR/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20191008
PL  - England
TA  - AIDS Res Ther
JT  - AIDS research and therapy
JID - 101237921
RN  - 0 (Anti-Retroviral Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Retroviral Agents/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Female
MH  - Follow-Up Studies
MH  - HIV Infections/*drug therapy/epidemiology
MH  - Humans
MH  - Infant
MH  - *Lost to Follow-Up
MH  - Male
MH  - Middle Aged
MH  - Nigeria/epidemiology
MH  - *Program Evaluation
MH  - Retrospective Studies
MH  - Viral Load/drug effects
MH  - Young Adult
PMC - PMC6784330
OTO - NOTNLM
OT  - ART
OT  - Loss to follow-up
OT  - Nigeria
COIS- The authors declare that they have no competing interests.
EDAT- 2019/10/09 06:00
MHDA- 2020/05/06 06:00
PMCR- 2019/10/08
CRDT- 2019/10/10 06:00
PHST- 2019/03/27 00:00 [received]
PHST- 2019/08/29 00:00 [accepted]
PHST- 2019/10/10 06:00 [entrez]
PHST- 2019/10/09 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
PHST- 2019/10/08 00:00 [pmc-release]
AID - 10.1186/s12981-019-0241-3 [pii]
AID - 241 [pii]
AID - 10.1186/s12981-019-0241-3 [doi]
PST - epublish
SO  - AIDS Res Ther. 2019 Oct 8;16(1):30. doi: 10.1186/s12981-019-0241-3.